CD4 and neoplasm: Furthermore, CD44+PD‐1−CD127lowCD4+ T cells, referred as unexhausted cells, significantly increase in responders treated with ICB,415 demonstrating that unexhausted CD4+ T cells expand to restrain tumor progression in response to ICB treatment.